Bharat Biotech’s nasal Covid booster gets nod for trial in India

FacebookTwitterWhatsAppCopy Link

New Delhi: first of its kind in India,§Drugs Controller General of India (DCGI) has given its approval to Bharat Biotech’s intranasal Covid vaccine candidate for clinical trials as Covid booster dose.

The central licensing authority (Drug Controller General of India) granted the permission for the world’s first nasal Covid shot as a booster.

DCGI gave an ‘in-principle’ approval and asked it to submit protocols for approval 3 weeks ago.